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The Wiskott–Aldrich syndrome (WAS) is a rare X-linked immunodeficiency disease with a
characteristic clinical phenotype that includes thrombocytopenia with small platelets,
eczema, recurrent infections caused by immunodeficiency, and an increased incidence of
autoimmune manifestations and malignancies. We present a patient who was diagnosed
with WAS in adulthood and was found to have bilateral bronchiectasis. Although recurrent
infections are common with Wiskott–Aldrich syndrome the association with bronchiectasis
has not been previously reported.
& 2007 Published by Elsevier Ltd.Introduction
The Wiskott–Aldrich syndrome (WAS) is a rare X-linked
immunodeficiency disease with a characteristic clinical
phenotype that includes thrombocytopenia with small
platelets, eczema, recurrent infections caused by immuno-
deficiency, and an increased incidence of autoimmune
manifestations and malignancies.1 Without aggressive treat-
ment, such as bone-marrow transplantation, most patientsPublished by Elsevier Ltd.
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.T. Sadikot).die by 10 years of age due to recurrent infections,
haemorrhage or autoimmune diseases.2,3 Here, we present
a case of Wiskott–Aldrich syndrome that we diagnosed in an
adult patient based on clinical findings. The patient
presented with a respiratory infection and was found to
have bilateral bronchiectasis. Although recurrent chest
infections are common due to an immunodeficient syndrome
the occurrence of bronchiectasis in patients with Wiskott–
Aldrich Syndrome has not been previously reported.
Case report
A 27 year old male patient with a history of life long eczema,
recurrent bacterial infections (cellulitis, pneumonia and
sinusitis), viral infections (Herpes zoster, molluscum, genital
warts) and a bleeding disorder requiring platelet transfu-
sions in the past presented with a 3 day history of productive
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Wiskott–Aldrich syndrome with bronchiectasis 55cough, fevers and shortness of breath. His family history was
notable for a brother, maternal uncle and grandfather who
had all succumbed at ages of o30 due to recurrent
infections and bleeding disorders (Figure 1).
On admission to the hospital he was alert awake and
oriented. He was febrile with a temperature of 101.2F,
tachycardic with pulse rate of 116 and tachypneic with a
respiratory rate of 24. ENT examination was notable for
nasal congestion. Cardiovascular system revealed tachycar-
dia with no murmurs, gallop or rub. Chest examination
showed coarse crackles with expiratory rhonchi in both
bases. Skin examination was significant for diffuse eczema
with vesicles on the left side along the distribution of upper
intercostal nerves suggestive of herpes (Figure 2) and
petechiae. He also had extensive genital warts. Other
physical examination was unremarkable.
His laboratory data were as follows: WBC count of 4.8
103 cells/mcL with lymphocyte count of 0.6 103 cells/mL,
CD4 376(590-1060), CD8 200(280-760), CD4/CD8 1.8(2-4)
and hemoglobin was 12.1 gm/dL. He was thrombocytopenic
with platelet count of 12,000 cells/mcL. Peripheral blood
smear showed thrombocytopenia with normal and small
sized platelets (Figure 3). Serum immunoglobulins showed
an IgM level of 31(77-220), IgA 161(68-378) and IgG
1180(590-1618) (mg/dL). HIV test was negative. Other
laboratory tests including CMP, blood cultures were nega-
tive. X-ray and CT scan of the chest (Figure 4) showed
bilateral basal bronchiectasis. Skin biopsy confirmed ecze-
ma. His HIV test was negative. He was admitted to the
hospital and treated with intravenous Vancomicin, Piper-
acillin and Acyclovir for 7 days, received platelet transfu-
sions and topical moisturising agents for eczema. Sputum
cultures grew S. Pneumoniae which was pan sensitive. The
diagnosis of Wiskott–Aldrich Syndrome was clinically sus-Family tree of our pa
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Figure 1 Family tree of our patient spected based on the presentation and later confirmed by
genetic testing for WASP gene mutation on X chromosome
using PCR-SSCP (Polymerase chain reaction-Single strand
conformation polymorphism) technique which revealed
missense mutation located in exons 2–3 of WASP gene. He
improved dramatically on antibiotics and was discharged
home with a plan to perform bone marrow transplantation.Discussion
Wiskott–Aldrich Syndrome (WAS) is a rare X-linked recessive
disease that was first recognized as a clinical syndrome
comprising of immunodeficiency, thrombocytopenia, bloody
diarrhea and eczema by Wiskott in 1937.4 The X-linked mode
of inheritance was subsequently demonstrated by Aldrich.5
The incidence of WAS is estimated between 1 and 10 in 1
million live births, although this is likely to be an under-
estimation, as patients lacking the classic phenotype are
often unrecognized.6,7 Clinical manifestations suggesting
WAS are often present at birth and consists of petechiae,
bruising, bloody diarrhea and persistent eczema. WAS
always causes persistent thrombocytopenia and, in its
complete form, also causes small platelets (mean platelet
volume is also decreased: 3.8 to 5.0 fl in WAS males,
compared with 7.1 to 10.5 fl in normal subjects), atopy,
cellular and humoral immunodeficiency, and an increased
risk of autoimmune disease and hematologic malignancy.
WAS is fatal without curative bone marrow transplantation,
but life expectancy has increased over time.1,2
Although Aldrich demonstrated an X-linked pattern of
inheritance for WAS in 1954, the molecular and genetic
defect of Wiskott–Aldrich Syndrome was not identified until
1994.8 WAS results from a genetic defect in a protein thattient showing X 
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Figure 2 Skin Eczema and Herpes Zoster (intercostal distribution).
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Figure 3 Peripheral smear showing thrombocytopenia and small platelets.
H. Mehta et al.56has now been termed as Wiskott–Aldrich syndrome protein
(WASp). The gene resides on Xp11.22-23, and its expression
is limited to cells of hematopoietic lineage. Several hundred
mutations associated with disease have now been discov-
ered in the WASP gene. A broad range of phenotypes has also
been associated with these mutations leading to differences
in severity of the presentation.9 The exact function of WASp
is not fully elucidated, but it seems to function as a bridge
between signaling and movement of the actin filaments in
the cytoskeleton.10,11 Many different mutations have been
identified that interfere with the protein binding to Cdc42
and Rac GTPases, among other binding partners, most of
which are involved in regulation of the actin cytoskeleton of
lymphocytes.12 The actin cytoskeleton is responsible for
cellular functions such as growth, endocytosis, exocytosis,
and cytokinesis. This also leads to defects in innate immunefunction of macrophages in particular phagocytosis and
chemotaxis of macrophages to the site of infection. Several
other immune deficiencies have also been noted in patients
with WAS. The severity of the immune deficiency varies
depending on the mutation and its effect on protein
expression. Both T and B lymphocytes are affected. The
number of B cells might be normal or moderately decreased.
Serum IgM levels are moderately decreased or can be normal
and increased. IgA and IgE levels are frequently increased
whereas serum IgG levels are within normal range. These
immune deficiencies lead to recurrent bacterial and viral
infections.10–12
Recurrent sinopulmonary infections are a hallmark of
WAS. In a large multiinstitutional study Sullivan et al.
surveyed 154 patients with WAS and found that the most
common infection in patients with WAS is otitis media (78%)
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Figure 4 CT Chest showing bronchiectasis.
Wiskott–Aldrich syndrome with bronchiectasis 57followed by pneumonia (45%) and sinusitis (24%).13 Thus
although recurrent upper and lower respiratory infections
are common in patients with WAS the occurrence of
bronchiectasis has not been previously reported in these
patients. This may be related to the fact that many of these
patients succumb at a young age often within eight years of
life.13,14 In a more recent survey an average age of eleven
years has been reported and occasional cases of patients
with WAS who live up to second and third decade have been
described.15–18 As the understanding of the pathogenesis of
the disease and therapeutic options broaden it is likely that
the outcome in these patients will improve. With increasing
survival the association of bronchiectasis with this immuno-
deficient syndrome is likely to increase.
The patient described showed classic clinical findings of
WAS including a persistent eczema, recurrent infections
both skin and respiratory and thrombocytopenia with small
platelets. His family history was significant for three male
members who had succumbed to bleeding disorder and
infections early in life. Thus the diagnosis was evident based
on clinical criteria. This was further confirmed by perform-
ing genetic testing for WAS protein and he was found to have
a missense mutation in exons 2–3 of the WASP gene on X
chromosome. His infection was appropriately treated with
broad spectrum antibiotics. Patient has also been offered
stem cell transplantation. WAS is fatal without curative bone
marrow transplantation.
In conclusion this case demonstrates the importance of
complete medical and family history as well as necessity of a
multidisciplinary approach and a broad differential diagnosis
when a congenital disease in adults is suspected. Although
there are few reports of WAS in adults, one should consider
this diagnosis in an appropriate clinical setting because of
variable penetrance of the disease. This case also illustrates
that Wiskott–Aldrich Syndrome should be considered in
patients with bronchiectasis in an appropriate clinical setting.Conflict of Interest Statement
The authors do not have any conflict of interest.References
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